News
hna Foundation collaborates in the development of a new drug against inflammatory bowel diseases
This support will help to develop and characterize a new immunomodulatory compound discovered by the IDIBELL group led by Dr. Josep Maria Aran.
CAC, IDIBELL and the Bellvitge University Hospital culminate the study What do you bet? about the risks of video games and gambling
The didactic material presented a year ago has been reviewed after its application as a pilot test with 3rd and 4th ESO students at the Virolai School and the Bellvitge Institute. The study concludes that educational programs prevent addictions to video games and gambling.
Researchers identify an effective therapeutic strategy against a subtype of melanoma currently with no treatment
Researchers have observed that, in the absence of glucose, tumor cells become sensitive to treatment with sorafenib, a drug that was approved years ago for other indications.
A new test to measure apathy is effective in Huntington’s disease
The test can distinguish different subtypes of apathy in Huntington’s patients, which opens up new perspectives for understanding this symptomatology, considered a marker of progression.
Symposium on Tobacco Control organized jointly with the World Health Organization
During the day, the Tobacco Control Scale was presented which describes the actions taken for tobacco control implemented in the 27 countries of the European Union plus 10 non-EU countries and which places the Spanish State in a situation very similar to that presented in the last edition in the year 2019
A new high-performance computing cluster to promote bioinformatics at IDIBELL
The new hardware will serve the research groups and the Bioinformatics Unit for huge data sets analysis. The speed and power of the equipment will make it possible to optimize resources and improve the consistency of the research results.
The Sociathlon association gives 12,665 euros for ALS research
The Sociathlon is a swimming, cycling, and athletics sporting event where 100% of registrations, donations to “number 0” and “in situ” collections go to two entities chosen annually
Agreement to boost and consolidate the Innovation and Health BioCluster project
The town councils of L’Hospitalet and Esplugues, the Bellvitge University Hospital, the Bellvitge Biomedical Research Institute (IDIBELL), the Catalan Institute of Oncology (ICO), the Sant Joan de Déu Hospital and the University of Barcelona have signed an agreement to promote and consolidate the Innovation and Health BioCluster project.
New mouse models boost personalized treatment research in endometrial cancer
To generate the new models a fresh biopsy of the original tumor was implanted into the same mouse tissue. This perfectly reproduces the original morphological and molecular characteristics, and therefore it anticipates the tumor evolution to choose the best treatment.